Literature DB >> 12916471

Unaltered agonist potency upon inducible 5-HT7(a) but not 5-HT4(b) receptor expression indicates agonist-independent association of 5-HT7(a) receptor and Gs.

Skjalg Bruheim1, Kurt A Krobert, Kjetil Wessel Andressen, Finn Olav Levy.   

Abstract

We compared adenylyl cyclase (AC) activation by the G protein-coupled human serotonin (5-HT) receptors 5-HT4(b) and 5-HT7(a) using an ecdysone-inducible expression system, which allowed for reproducible expression of increasing receptor densities in clonal HEK293 (EcR293) cell lines. Low constitutive expression of receptors (2-70 fmol/mg protein) was observed and could be titrated up to 50-200-fold (approximately 400-7000 fmol/mg protein) by the ecdysone analogue ponasterone A. Although 5-HT-stimulated AC activity increased with receptor density, interclonal variation precluded comparisons of coupling efficiency. Interestingly, the potency of 5-HT to stimulate AC increased with increasing receptor density only in clones expressing 5-HT4(b) receptors. The potency for 5-HT did not change in clones expressing 5-HT7(a) receptors, even though 5-HT-stimulated AC activity approached asymptotic levels. This indicates that potency of 5-HT for stimulation of AC through the 5-HT7(a) receptor is independent of receptor-Gs stoichiometry and is consistent with a model where the 5-HT7(a) receptors are tightly associated with G protein, independent of agonist binding. This supports the existence of a complex between inactive receptor and G protein, as predicted by the cubic ternary complex model. In such a system, spare receptors do not lead to increased potency of an agonist with increased receptor density.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12916471

Source DB:  PubMed          Journal:  Receptors Channels        ISSN: 1060-6823


  13 in total

Review 1.  Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders.

Authors:  Marcello Leopoldo; Enza Lacivita; Francesco Berardi; Roberto Perrone; Peter B Hedlund
Journal:  Pharmacol Ther       Date:  2010-10-20       Impact factor: 12.310

2.  Antagonist interaction with the human 5-HT(7) receptor mediates the rapid and potent inhibition of non-G-protein-stimulated adenylate cyclase activity: a novel GPCR effect.

Authors:  M T Klein; M Teitler
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

3.  Cyclic AMP-dependent inotropic effects are differentially regulated by muscarinic G(i)-dependent constitutive inhibition of adenylyl cyclase in failing rat ventricle.

Authors:  R I Hussain; F Afzal; H K Mørk; J M Aronsen; I Sjaastad; J-B Osnes; T Skomedal; F O Levy; K A Krobert
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

4.  New concept of spare receptors and effectors.

Authors:  Y Marunaka; N Niisato; H Miyazaki
Journal:  J Membr Biol       Date:  2005-01       Impact factor: 1.843

5.  The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity.

Authors:  J A M Smith; D T Beattie; D Marquess; J P Shaw; R G Vickery; P P A Humphrey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-16       Impact factor: 3.000

6.  Prucalopride is a partial agonist through human and porcine atrial 5-HT4 receptors: comparison with recombinant human 5-HT4 splice variants.

Authors:  Kurt A Krobert; Trond Brattelid; Finn Olav Levy; Alberto J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-13       Impact factor: 3.000

7.  A comparison of the pharmacological properties of guinea-pig and human recombinant 5-HT4 receptors.

Authors:  R G Vickery; N Mai; E Kaufman; D T Beattie; T Pulido-Rios; M O'Keefe; P P A Humphrey; J A M Smith
Journal:  Br J Pharmacol       Date:  2007-02-12       Impact factor: 8.739

Review 8.  The serotonin 5-HT7 receptors: two decades of research.

Authors:  Evelien Gellynck; Karen Heyninck; Kjetil W Andressen; Guy Haegeman; Finn Olav Levy; Peter Vanhoenacker; Kathleen Van Craenenbroeck
Journal:  Exp Brain Res       Date:  2013-09-17       Impact factor: 1.972

9.  Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists.

Authors:  Jessica A Knight; Carol Smith; Nicole Toohey; Michael T Klein; Milt Teitler
Journal:  Mol Pharmacol       Date:  2008-11-07       Impact factor: 4.436

10.  Cloning, pharmacological characterisation and tissue distribution of a novel 5-HT4 receptor splice variant, 5-HT4(i).

Authors:  Trond Brattelid; Ane M Kvingedal; Kurt A Krobert; Kjetil W Andressen; Trond Bach; Marit E Hystad; Alberto J Kaumann; Finn Olav Levy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-30       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.